AstraZeneca PLC (AZN)vsWalt Disney Company (DIS)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
DIS
Walt Disney Company
$108.02
-0.59%
COMMUNICATION SERVICES · Cap: $188.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Walt Disney Company generates 61% more annual revenue ($97.26B vs $60.44B). AZN leads profitability with a 17.2% profit margin vs 11.5%. AZN appears more attractively valued with a PEG of 1.52. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
DIS
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+16.1%
Fair Value
$126.48
Current Price
$108.02
$18.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Generating 4.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 29.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : DIS
The strongest argument for DIS centers on Market Cap, P/E Ratio, Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : DIS
The primary concerns for DIS are Altman Z-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while DIS is a value play — different risk/reward profiles.
DIS carries more volatility with a beta of 1.42 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
DIS generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 57/100), backed by strong 17.2% margins and 12.5% revenue growth. DIS offers better value entry with a 16.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Walt Disney Company
COMMUNICATION SERVICES · ENTERTAINMENT · USA
The Walt Disney Company, commonly known as Disney, is an American diversified multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?